KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Q22*1
Panitumumab	Colon Mucinous Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID1131 A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC) PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC	civic
KRAS Amplification1
Carboplatin + Docetaxel + SorafenibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1497 Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC	civic
KRAS G12D4
Vemurafenib	Hairy Cell Leukemia	Predictive	C	Supports Resistance	2	accepted	EID1580 One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC	civic
Dabrafenib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID91 A 63 year old patient was diagnosed with lung adenocarcinoma and received several treatment regimens over approximately three years, including carboplatin/paclitaxel, erlotinib, pemetrexed/bevacizumab… (full text at CIViC) PMID 23524406 · Rudin et al., 2013 · Open in CIViC	civic
Dactolisib + SelumetinibCombination	Lung Adenocarcinoma	Predictive	D	Supports
KRAS RS617643701
Cisplatin	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	3	accepted	EID872 In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was adde… (full text at CIViC) PMID 25081901 · Chung et al., 2014 · Open in CIViC	civic
KRAS Mutation23
Refametinib + SorafenibCombination	Hepatocellular Carcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID1642 Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was per… (full text at CIViC) PMID 25294897 · Lim et al., 2014 · Open in CIViC	civic
Salirasib	Lung Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1218 In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival … (full text at CIViC) PMID 21847063 · Riely et al., 2011 · Open in CIViC	civic
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER
KRAS G12A1
Erlotinib + GefitinibSubstitutes	Lung Adenocarcinoma	Predictive	B	Supports Resistance	3	accepted	EID251 KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) wer… (full text at CIViC) PMID 19794967 · Marchetti et al., 2009 · Open in CIViC	civic
KRAS G12D + TSC1 Loss-of-functionKRAS TSC11
Sirolimus	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID154 Following rapamycin treatment of mice with KrasG12D-induced lung adenocarcinomas, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, i… (full text at CIViC) PMID 19966866 · Liang et al., 2010 · Open in CIViC	civic
KRAS A146V1
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID794 Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led… (full text at CIViC) PMID 24836576 · Van Allen et al., 2014 · Open in CIViC	civic
KRAS G12C4
Divarasib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID11652 A phase 1 clinical study conducted with Divarasib in a total of 137 patients, of which 60 patients had NSCLC with G12C mutation in the KRAS gene. Confirmed response was noted in 53.4% (95% CI; 39.9 to… (full text at CIViC) PMID 37611121 · Sacher et al., 2023 · Open in CIViC	civic
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID1142 83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size a… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Sotorasib
KRAS G12V3
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	1	accepted	EID1143 83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 accordin… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Palbociclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	1	accepted	EID795 In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treat… (full text at CIViC) PMID 20609353 · Puyol et al., 2010 · Open in CIViC	civic
Cetuximab
KRAS G12/G132
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID35 In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201). PMID 15696205 · Pao et al., 2005 · Open in CIViC	civic
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Resistance	3	accepted	EID6295 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
KRAS G13D6
Pictilisib	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID2041 This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID306 KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS. PMID 20978259 · De Roock et al., 2010 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B
KRAS Exon 2 Mutation2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Resistance	5	accepted	EID993 KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone. 42% of… (full text at CIViC) PMID 18946061 · Karapetis et al., 2008 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID250 Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab. PMID 16618717 · Lièvre et al., 2006 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved	Mar 16, 2023	openfda
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,652)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 798 recruiting · 366 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 401–450 of 1,652 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05317858	Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets(LIMITLESS)	recruiting	Phase 3	30	InSightecINDUSTRY	3	Aug 19, 2026	clinicaltrials
NCT07128303	Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors	recruiting	Phase 1	476	Gilead SciencesINDUSTRY	3	Aug 19, 2026	clinicaltrials
NCT07214298	Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma	recruiting	Phase 1 / Phase 2	35	Roswell Park Cancer InstituteOTHER	1	Aug 19, 2026	clinicaltrials
NCT07774247	Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma(AB-TCZ)	not yet recruiting	Phase 2	51	CHA UniversityOTHER	1	Aug 19, 2026	clinicaltrials
NCT07774611	An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors	not yet recruiting	Phase 1 / Phase 2	180	Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY	1	Aug 19, 2026	clinicaltrials
NCT04598009	Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma	recruiting	Phase 2	25	University of California, San FranciscoOTHER	1	Aug 18, 2026	clinicaltrials
NCT04929041	Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative	active not recruiting	Phase 2 / Phase 3	427	National Cancer Institute (NCI)NIH	1	Aug 18, 2026	clinicaltrials
NCT06239220	PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC	recruiting	Phase 2	25	Dana-Farber Cancer InstituteOTHER	1	Aug 18, 2026	clinicaltrials
NCT06514027	Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations	recruiting	Phase 2	30	BeBetter Med IncINDUSTRY	1	Aug 18, 2026	clinicaltrials
NCT06731907	A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)	recruiting	Phase 2	90	Merck Sharp & Dohme LLCINDUSTRY	11	Aug 18, 2026	clinicaltrials
NCT06743126	SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma(SUPRAME)	recruiting	Phase 3	360	Immatics US, Inc.INDUSTRY	6	Aug 18, 2026	clinicaltrials
NCT06792695	A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer(CANTOR)	recruiting	Phase 2	80	AstraZenecaINDUSTRY	12	Aug 18, 2026	clinicaltrials
NCT07470853	A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.	recruiting	Phase 1	265	Whitehawk Therapeutics, Inc.INDUSTRY	1	Aug 18, 2026	clinicaltrials
NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study	enrolling by invitation	Phase 3	5,000	ExelixisINDUSTRY	1	Aug 18, 2026	clinicaltrials
NCT03646617	Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma(RadVax)	active not recruiting	Phase 2	62	Abramson Cancer Center at Penn MedicineOTHER	1	Aug 17, 2026	clinicaltrials
NCT03965468	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC(CHESS)	active not recruiting	Phase 2	96	ETOP IBCSG Partners FoundationNETWORK	4	Aug 17, 2026	clinicaltrials
NCT04895709	A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	1,109	Bristol-Myers SquibbINDUSTRY	8	Aug 17, 2026	clinicaltrials
NCT05415709	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer	active not recruiting	Early Phase 1	35	Ohio State University Comprehensive Cancer CenterOTHER	1	Aug 17, 2026	clinicaltrials
NCT05624996	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer	recruiting	Phase 3	474	NRG OncologyOTHER	2	Aug 17, 2026	clinicaltrials
NCT05919264	FOG-001 in Locally Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	619	Parabilis Medicines, Inc.INDUSTRY	2	Aug 17, 2026	clinicaltrials
NCT06001385	HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE)	active not recruiting	Phase 2	313	Center for International Blood and Marrow Transplant ResearchNETWORK	1	Aug 17, 2026	clinicaltrials
NCT06532279	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer	recruiting	Phase 2	98	NRG OncologyOTHER	1	Aug 17, 2026	clinicaltrials
NCT07166406	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	recruiting	Phase 3	226	NRG OncologyOTHER	2	Aug 17, 2026	clinicaltrials
NCT07341867	Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype	recruiting	Phase 1	90	Andrew Hantel, MDOTHER	1	Aug 17, 2026	clinicaltrials
NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Aug 17, 2026	clinicaltrials
NCT07441681	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin	recruiting	Phase 3	454	NRG OncologyOTHER	1	Aug 17, 2026	clinicaltrials
NCT07735546	A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma	not yet recruiting	Phase 1	100	Umoja BiopharmaINDUSTRY	0	Aug 17, 2026	clinicaltrials
NCT07768436	A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer	recruiting	Phase 2	76	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 17, 2026	clinicaltrials
NCT03847428	Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2)	active not recruiting	Phase 3	908	AstraZenecaINDUSTRY	24	Aug 14, 2026	clinicaltrials
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	recruiting	Phase 2	80	Roswell Park Cancer InstituteOTHER	1	Aug 14, 2026	clinicaltrials
NCT05335941	A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma	active not recruiting	Phase 2	10	M.D. Anderson Cancer CenterOTHER	1	Aug 14, 2026	clinicaltrials
NCT05722327	Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	active not recruiting	Phase 1	24	M.D. Anderson Cancer CenterOTHER	1	Aug 14, 2026	clinicaltrials
NCT05853575	Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)	active not recruiting	Phase 2	200	Mirati Therapeutics Inc.INDUSTRY	18	Aug 14, 2026	clinicaltrials
NCT06074588	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	active not recruiting	Phase 3	556	Merck Sharp & Dohme LLCINDUSTRY	25	Aug 14, 2026	clinicaltrials
NCT07262567	Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer	recruiting	Phase 3	320	Genfleet Therapeutics (Shanghai) Inc.INDUSTRY	1	Aug 14, 2026	clinicaltrials
NCT02971501	Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases	active not recruiting	Phase 2	5	National Cancer Institute (NCI)NIH	1	Aug 13, 2026	clinicaltrials
NCT03332797	A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer	active not recruiting	Phase 1	181	Genentech, Inc.INDUSTRY	5	Aug 13, 2026	clinicaltrials
NCT03858322	'ADVANCE' (A Pilot Trial)	active not recruiting	Phase 1	41	Dana-Farber Cancer InstituteOTHER	1	Aug 13, 2026	clinicaltrials
NCT04603807	A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases	active not recruiting	Phase 3	217	Hoffmann-La RocheINDUSTRY	18	Aug 13, 2026	clinicaltrials
NCT05671510	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors(PRESERVE-003)	active not recruiting	Phase 3	630	OncoC4, Inc.INDUSTRY	12	Aug 13, 2026	clinicaltrials
NCT06040970	Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer	recruiting	Phase 1 / Phase 2	54	Icahn School of Medicine at Mount SinaiOTHER	1	Aug 13, 2026	clinicaltrials
NCT06120075	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies(ARC-27)	active not recruiting	Phase 1	91	Arcus Biosciences, Inc.INDUSTRY	1	Aug 13, 2026	clinicaltrials
NCT06956001	Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation	recruiting	Phase 3	300	Allist Pharmaceuticals, Inc.INDUSTRY	1	Aug 13, 2026	clinicaltrials
NCT07042802	A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer	recruiting	Phase 1 / Phase 2	180	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Aug 13, 2026	clinicaltrials
NCT03943173	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	active not recruiting	Early Phase 1	15	M.D. Anderson Cancer CenterOTHER	1	Aug 12, 2026	clinicaltrials
NCT04115163	Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer	active not recruiting	Phase 2	67	Anne NoonanOTHER	1	Aug 12, 2026	clinicaltrials
NCT05544136	A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer	recruiting	Phase 2	12	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 12, 2026	clinicaltrials
NCT06797336	A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors	recruiting	Phase 1	240	PAQ Therapeutics, Inc.INDUSTRY	2	Aug 12, 2026	clinicaltrials
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	Phase 1 / Phase 2	75	National Cancer Institute (NCI)NIH	1	Aug 11, 2026	clinicaltrials
NCT02884648	Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery	active not recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,652)

Linked publications (113)